Ocugen vs Taysha Gene Therapies
OCGN and TSHA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OCGN and TSHA compare
Taysha Gene Therapies is the larger company, worth 4.8 times as much as Ocugen ($1.3B against $281M).
Taysha Gene Therapies scores higher on the StockData Score (5 against 1 for Ocugen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OCGN | TSHA |
|---|---|---|
| Size and price | ||
| Market cap | $281M | $1.3B |
| Share price | $0.828 | $4.10 |
| Change, 1 year | −38.2% | −6.0% |
| Change, 5 years | −89.3% | −69.6% |
| Beta (5Y) | 1.65 | 2.09 |
| Employees | 116 | 99 |
| StockData Score | ||
| Total score | 1 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 244× |
| P/B | – | 3.7× |
| FCF yield | −22.8% | −10.6% (better) |
| Growth | ||
| Revenue growth (TTM) | – | −13.1% |
| Revenue growth, 5Y average | 152% | – |
| Profitability | ||
| Operating margin | – | −2935% |
| Net margin | – | −2845% |
| FCF margin | – | −2583% |
| Return on equity | – | −54.2% |
| Financial health | ||
| Debt / equity | – | 0.13 |
| Interest coverage | −6.8× (better) | −5193.8× |
| Current ratio | 0.77 | 18.56 (better) |
| Altman Z-score | −6.98 | 7.47 (better) |
| Piotroski F-score | 0 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 42.8% | 91.9% |
| Held by insiders | 2.4% | 10.7% |
| Insider net buying, 12 months | −$1.1M (better) | −$6.1M |
| Short interest, % of float | 32.5% | 18.4% |
Go deeper
- OCGN stock overview
- OCGN income statement
- OCGN valuation and score
- TSHA stock overview
- TSHA income statement
- TSHA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.